Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation.
Kumar A, Soumerai JD, Abramson JS, Barnes JA, Caron PC, Chhabra S, Chabowska M, Dogan A, Falchi L, Grieve C, Haydu JE, Johnson PC, Joseph A, Kelly H, Labarre A, Lue JK, Martignetti R, Mi J, Moskowitz AJ, Owens CN, Plummer S, Puccio M, Salles GA, Seshan VE, Simkins E, Slupe N, Zhang H, Zelenetz AD.
Kumar A, et al. Among authors: chhabra s.
Blood. 2024 Oct 22:blood.2024025563. doi: 10.1182/blood.2024025563. Online ahead of print.
Blood. 2024.
PMID: 39437708
Free article.